Last reviewed · How we verify
Akineton (BIPERIDEN)
Akineton (Biperiden) is a small molecule anticholinergic medication originally developed by AbbVie and currently owned by the same company. It targets the muscarinic acetylcholine receptor M1 and is used to treat various conditions related to Parkinson's disease, including arteriosclerotic parkinsonism, extrapyramidal disease, and postencephalitic parkinsonism. Akineton was first approved by the FDA in 1959 and remains off-patent, with no active Orange Book patents. It has a half-life of 24 hours and bioavailability of 30%. As an anticholinergic, Akineton can have significant side effects, particularly in older adults, and its use should be carefully monitored.
At a glance
| Generic name | BIPERIDEN |
|---|---|
| Sponsor | AbbVie |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptor M1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
Key clinical trials
- Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability (PHASE4)
- Biperiden Trial for Epilepsy Prevention (PHASE3)
- Use of Biperiden for the Prevention of Post-traumatic Epilepsy (PHASE3)
- Cocaine/Crack and Reduction of Compulsion With Biperiden (PHASE3)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients (PHASE2,PHASE3)
- Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Akineton CI brief — competitive landscape report
- Akineton updates RSS · CI watch RSS
- AbbVie portfolio CI